=Cellect Biotechnology (APOP) : FDA grants orphan drug status

Stock: APOP (NASDAQ)
Headquarters: Israel
Founded: 1986


Cellect Biotechnology: FDA grants orphan drug status to Cellect's ApoGraft for Acute GvHD and Chronic GvHD

• Co announced that the FDA has granted orphan drug designation for Cellect's ApoGraft for the prevention of acute and chronic graft versus host disease in transplant patients. GvHD is a transplant associated disease representing an outcome of two immune systems crashing into each other.
• In many transplantations from donors, and especially in Bone Marrow Transplantations, the transplanted immune mature cells (as opposed to stem cells) attack the host (patient receiving the transplant) and create severe morbidity and in many cases even death.

***

Cellect Biotechnology Ltd. focuses on developing solutions for immune system regeneration in Israel. The company is developing a product that is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents, as well as used to improve the outcome of bone marrow transplantation. Its product under development includes ApoTainer selection kit, which is used in novel ApoGraft process for hematopoietic stem cell transplantation. Cellect Biotechnology Ltd. was founded in 2011 and is based in Kfar Saba, Israel.